GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » Cyclically Adjusted PS Ratio

Durect (Durect) Cyclically Adjusted PS Ratio : 0.57 (As of Apr. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Durect Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Durect's current share price is $0.9313. Durect's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.62. Durect's Cyclically Adjusted PS Ratio for today is 0.57.

The historical rank and industry rank for Durect's Cyclically Adjusted PS Ratio or its related term are showing as below:

DRRX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.31   Med: 3.73   Max: 11.68
Current: 0.56

During the past years, Durect's highest Cyclically Adjusted PS Ratio was 11.68. The lowest was 0.31. And the median was 3.73.

DRRX's Cyclically Adjusted PS Ratio is ranked better than
84.1% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs DRRX: 0.56

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Durect's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.090. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.62 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Durect Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Durect's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durect Cyclically Adjusted PS Ratio Chart

Durect Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.76 8.24 4.33 2.00 0.36

Durect Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.64 2.93 1.49 0.36

Competitive Comparison of Durect's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Durect's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durect's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Durect's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Durect's Cyclically Adjusted PS Ratio falls into.



Durect Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Durect's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.9313/1.62
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Durect's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Durect's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.09/129.4194*129.4194
=0.090

Current CPI (Dec. 2023) = 129.4194.

Durect Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.570 99.695 0.740
201406 0.414 100.560 0.533
201409 0.381 100.428 0.491
201412 0.375 99.070 0.490
201503 0.419 99.621 0.544
201506 0.374 100.684 0.481
201509 0.394 100.392 0.508
201512 0.427 99.792 0.554
201603 0.295 100.470 0.380
201606 0.238 101.688 0.303
201609 0.271 101.861 0.344
201612 0.252 101.863 0.320
201703 0.322 102.862 0.405
201706 0.303 103.349 0.379
201709 1.366 104.136 1.698
201712 1.307 104.011 1.626
201803 0.227 105.290 0.279
201806 0.211 106.317 0.257
201809 0.496 106.507 0.603
201812 0.021 105.998 0.026
201903 0.255 107.251 0.308
201906 0.242 108.070 0.290
201909 0.560 108.329 0.669
201912 0.320 108.420 0.382
202003 0.081 108.902 0.096
202006 1.181 108.767 1.405
202009 0.090 109.815 0.106
202012 0.109 109.897 0.128
202103 0.102 111.754 0.118
202106 0.101 114.631 0.114
202109 0.095 115.734 0.106
202112 0.321 117.630 0.353
202203 0.084 121.301 0.090
202206 0.091 125.017 0.094
202209 0.526 125.227 0.544
202212 0.145 125.222 0.150
202303 0.086 127.348 0.087
202306 0.085 128.729 0.085
202309 0.063 129.860 0.063
202312 0.090 129.419 0.090

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Durect  (NAS:DRRX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Durect Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Durect's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Durect (Durect) Business Description

Industry
Traded in Other Exchanges
Address
10260 Bubb Road, Cupertino, CA, USA, 95014
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
Executives
Judith J. Robertson director 10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis director 364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp officer: Chief Financial Officer C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel director 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia director ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman officer: Chief Medical Officer C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice officer: Sr. VP Operations & Corp QA 10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg officer: Chief Financial Officer 10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown director, officer: President & CEO 10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105